Clearly, the NVS-MNTA Lovenox agreement from 2003 did not foresee MNTA’s owning IP capable of blocking a competitor’s entry into the market. That’s why I think the sharing of legal expenses in this instance is unclear.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”